Muscle RAS oncogene homolog (MRAS)

Muscle RAS oncogene homolog (MRAS) encodes a member of the small GTPase superfamily, specifically the Ras family of signaling proteins[1][2][3][4]. MRAS acts as a membrane-associated signal transducer, regulating diverse signaling pathways such as MAP kinase and PI3-K/Akt, which are central to cellular processes including growth, survival, differentiation, cytoskeletal organization, and migration[1][2][3][4]. While MRAS shares effector interactions with classical RAS proteins (HRAS, KRAS, NRAS), it also functions uniquely as a component of the SHOC2–protein phosphatase 1 (PP1) complex, modulating RAF kinase activity for efficient MAPK/ERK pathway activation[3]. MRAS expression is tightly regulated and is particularly noted in heart, brain, skeletal muscle, and developmental tissues[2][3][4]. Germline activating mutations in MRAS cause Noonan syndrome, while upregulation and/or altered activity may contribute to the pathogenesis of certain cancers and cardiovascular disease[3][4]. No direct drugs currently target MRAS, but its pivotal position in major signaling cascades makes it an area of ongoing biological and therapeutic interest[3][4].

Other names

Ras-related protein M-RasR-Ras3RRAS3M-RasNS11muscle and microspikes RAS

No clinically approved drugs directly target MRAS Agents affecting the downstream MAPK/ERK pathway (indirect effect) Drugs modulating SHOC2/PP1 complex signaling (investigational/mechanistic, not clinical)